Search

Your search keyword '"Vitanza, Nicholas A."' showing total 305 results
Start Over Author "Vitanza, Nicholas A."
305 results on '"Vitanza, Nicholas A."'

1. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

Author

Vitanza, Nicholas A., Ronsley, Rebecca, Choe, Michelle, Seidel, Kristy, Huang, Wenjun, Rawlings-Rhea, Stephanie D., Beam, Madison, Steinmetzer, Leonel, Wilson, Ashley L., Brown, Christopher, Beebe, Adam, Lindgren, Catherine, Gustafson, Joshua A., Wein, Amy, Holtzclaw, Susan, Hoeppner, Corrine, Goldstein, Hannah E., Browd, Samuel R., Hauptman, Jason S., Lee, Amy, Ojemann, Jeffrey G., Crotty, Erin E., Leary, Sarah E. S., Perez, Francisco A., Wright, Jason N., Alonso, Marta M., Dun, Matthew D., Foster, Jessica B., Hurst, Diana, Kong, Ada, Thomsen, Alison, Orentas, Rimas J., Albert, Catherine M., Pinto, Navin, Annesley, Colleen, Gardner, Rebecca A., Ho, On, Pattabhi, Sowmya, Gust, Juliane, Wendler, Jason P., Park, Julie R., and Jensen, Michael C.

Published
2025
Full Text
View/download PDF

3. An international study presenting a federated learning AI platform for pediatric brain tumors

Author

Lee, Edward H., Han, Michelle, Wright, Jason, Kuwabara, Michael, Mevorach, Jacob, Fu, Gang, Choudhury, Olivia, Ratan, Ujjwal, Zhang, Michael, Wagner, Matthias W., Goetti, Robert, Toescu, Sebastian, Perreault, Sebastien, Dogan, Hakan, Altinmakas, Emre, Mohammadzadeh, Maryam, Szymanski, Kathryn A., Campen, Cynthia J., Lai, Hollie, Eghbal, Azam, Radmanesh, Alireza, Mankad, Kshitij, Aquilina, Kristian, Said, Mourad, Vossough, Arastoo, Oztekin, Ozgur, Ertl-Wagner, Birgit, Poussaint, Tina, Thompson, Eric M., Ho, Chang Y., Jaju, Alok, Curran, John, Ramaswamy, Vijay, Cheshier, Samuel H., Grant, Gerald A., Wong, S. Simon, Moseley, Michael E., Lober, Robert M., Wilms, Mattias, Forkert, Nils D., Vitanza, Nicholas A., Miller, Jeffrey H., Prolo, Laura M., and Yeom, Kristen W.

Published
2024
Full Text
View/download PDF

4. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.

Author

Jackson, Evangeline, Duchatel, Ryan, Staudt, Dilana, Persson, Mika, Mannan, Abdul, Yadavilli, Sridevi, Parackal, Sarah, Game, Shaye, Chong, Wai, Jayasekara, W, Le Grand, Marion, Kearney, Padraic, Douglas, Alicia, Findlay, Izac, Germon, Zacary, McEwen, Holly, Beitaki, Tyrone, Patabendige, Adjanie, Skerrett-Byrne, David, Nixon, Brett, Smith, Nathan, Day, Bryan, Manoharan, Neevika, Nagabushan, Sumanth, Hansford, Jordan, Govender, Dinisha, McCowage, Geoffrey, Firestein, Ron, Howlett, Meegan, Endersby, Raelene, Gottardo, Nicholas, Alvaro, Frank, Larsen, Martin, Colino-Sanguino, Yolanda, Valdés-Mora, Fatima, Rakotomalala, Andria, Meignan, Samuel, Pasquier, Eddy, Andre, Nicolas, Hulleman, Esther, Eisenstat, David, Vitanza, Nicholas, Nazarian, Javad, Koschmann, Carl, Mueller, Sabine, Cain, Jason, Dun, Matthew, and Waszak, Sebastian

Abstract

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9-11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. However, further work is needed to identify the mechanisms of response of DIPGs to ONC201 treatment and to determine whether recurring genomic features influence response. Using a systems-biological approach, we showed that ONC201 elicits potent agonism of the mitochondrial protease ClpP to drive proteolysis of electron transport chain and tricarboxylic acid cycle proteins. DIPGs harboring PIK3CA-mutations showed increased sensitivity to ONC201, while those harboring TP53-mutations were more resistant. Metabolic adaptation and reduced sensitivity to ONC201 was promoted by redox-activated PI3K/Akt signaling, which could be counteracted using the brain penetrant PI3K/Akt inhibitor, paxalisib. Together, these discoveries coupled with the powerful anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib have provided the rationale for the ongoing DIPG/DMG phase II combination clinical trial NCT05009992.

Published
2023

5. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors

Author

Pinto, Navin, Albert, Catherine M., Taylor, Mallory R., Ullom, Heidi B., Wilson, Ashley L., Huang, Wenjun, Wendler, Jason, Pattabhi, Sowmya, Seidel, Kristy, Brown, Christopher, Gustafson, Joshua A., Rawlings-Rhea, Stephanie D., Cheeney, Safia H.E., Burleigh, Katelyn, Gustafson, Heather H., Orentas, Rimas J., Vitanza, Nicholas A., Gardner, Rebecca A., Jensen, Michael C., and Park, Julie R.

Published
2024
Full Text
View/download PDF

6. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.

Author

Messinger, Dana, Harris, Micah, Cummings, Jessica, Thomas, Chase, Yang, Tao, Sweha, Stefan, Woo, Rinette, Siddaway, Robert, Burkert, Martin, Stallard, Stefanie, Qin, Tingting, Mullan, Brendan, Siada, Ruby, Ravindran, Ramya, Niculcea, Michael, Dowling, Abigail, Bradin, Joshua, Ginn, Kevin, Gener, Melissa, Dorris, Kathleen, Vitanza, Nicholas, Schmidt, Susanne, Spitzer, Jasper, Li, Jiang, Filbin, Mariella, Cao, Xuhong, Castro, Maria, Lowenstein, Pedro, Mody, Rajen, Chinnaiyan, Arul, Desprez, Pierre-Yves, McAllister, Sean, Dun, Matthew, Hawkins, Cynthia, Waszak, Sebastian, Venneti, Sriram, Koschmann, Carl, and Yadav, Viveka

Subjects
CBD, DMG, ID1, ROS, invasion/migration, Animals, Humans, Mice, Brain, Brain Neoplasms, Calcium-Binding Proteins, Extracellular Matrix Proteins, Glioma, Histones, Inhibitor of Differentiation Protein 1, Mutation, Signal Transduction
Abstract

BACKGROUND: Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism behind tumor invasion. Previous reports demonstrate upregulation of the protein ID1 with H3K27M and ACVR1 mutations in DMG, but this has not been confirmed in human tumors or therapeutically targeted. METHODS: Whole exome, RNA, and ChIP-sequencing was performed on the ID1 locus in DMG tissue. Scratch-assay migration and transwell invasion assays of cultured cells were performed following shRNA-mediated ID1-knockdown. In vitro and in vivo genetic and pharmacologic [cannabidiol (CBD)] inhibition of ID1 on DMG tumor growth was assessed. Patient-reported CBD dosing information was collected. RESULTS: Increased ID1 expression in human DMG and in utero electroporation (IUE) murine tumors is associated with H3K27M mutation and brainstem location. ChIP-sequencing indicates ID1 regulatory regions are epigenetically active in human H3K27M-DMG tumors and prenatal pontine cells. Higher ID1-expressing astrocyte-like DMG cells share a transcriptional program with oligo/astrocyte-precursor cells (OAPCs) from the developing human brain and demonstrate upregulation of the migration regulatory protein SPARCL1. Genetic and pharmacologic (CBD) suppression of ID1 decreases tumor cell invasion/migration and tumor growth in H3.3/H3.1K27M PPK-IUE and human DIPGXIIIP* in vivo models of pHGG. The effect of CBD on cell proliferation appears to be non-ID1 mediated. Finally, we collected patient-reported CBD treatment data, finding that a clinical trial to standardize dosing may be beneficial. CONCLUSIONS: H3K27M-mediated re-activation of ID1 in DMG results in a SPARCL1+ migratory transcriptional program that is therapeutically targetable with CBD.

Published
2023

7. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.

Author

Przystal, Justyna, Cianciolo Cosentino, Chiara, Yadavilli, Sridevi, Zhang, Jie, Laternser, Sandra, Bonner, Erin, Prasad, Rachna, Dawood, Adam, Lobeto, Nina, Chin Chong, Wai, Biery, Matt, Myers, Carrie, Olson, James, Panditharatna, Eshini, Kritzer, Bettina, Mourabit, Sulayman, Vitanza, Nicholas, Filbin, Mariella, de Iuliis, Geoffry, Dun, Matthew, Koschmann, Carl, Cain, Jason, Grotzer, Michael, Waszak, Sebastian, Mueller, Sabine, and Nazarian, Javad

Subjects
ClpP, ONC201, ONC206, diffuse midline glioma (DMG), integrated stress response (ISR), Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Lineage, Child, Energy Metabolism, Glioma, Heterocyclic Compounds, 4 or More Rings, Humans, Mice, Zebrafish
Abstract

BACKGROUND: Pediatric diffuse midline gliomas (DMGs) are incurable childhood cancers. The imipridone ONC201 has shown early clinical efficacy in a subset of DMGs. However, the anticancer mechanisms of ONC201 and its derivative ONC206 have not been fully described in DMGs. METHODS: DMG models including primary human in vitro (n = 18) and in vivo (murine and zebrafish) models, and patient (n = 20) frozen and FFPE specimens were used. Drug-target engagement was evaluated using in silico ChemPLP and in vitro thermal shift assay. Drug toxicity and neurotoxicity were assessed in zebrafish models. Seahorse XF Cell Mito Stress Test, MitoSOX and TMRM assays, and electron microscopy imaging were used to assess metabolic signatures. Cell lineage differentiation and drug-altered pathways were defined using bulk and single-cell RNA-seq. RESULTS: ONC201 and ONC206 reduce viability of DMG cells in nM concentrations and extend survival of DMG PDX models (ONC201: 117 days, P = .01; ONC206: 113 days, P = .001). ONC206 is 10X more potent than ONC201 in vitro and combination treatment was the most efficacious at prolonging survival in vivo (125 days, P = .02). Thermal shift assay confirmed that both drugs bind to ClpP, with ONC206 exhibiting a higher binding affinity as assessed by in silico ChemPLP. ClpP activation by both drugs results in impaired tumor cell metabolism, mitochondrial damage, ROS production, activation of integrative stress response (ISR), and apoptosis in vitro and in vivo. Strikingly, imipridone treatment triggered a lineage shift from a proliferative, oligodendrocyte precursor-like state to a mature, astrocyte-like state. CONCLUSION: Targeting mitochondrial metabolism and ISR activation effectively impairs DMG tumorigenicity. These results supported the initiation of two pediatric clinical trials (NCT05009992, NCT04732065).

Published
2022

9. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.

Author

Findlay, Izac, De Iuliis, Geoffry, Duchatel, Ryan, Jackson, Evangeline, Vitanza, Nicholas, Cain, Jason, Waszak, Sebastian, and Dun, Matthew

Subjects
Animals, Brain Neoplasms, Child, Child, Preschool, Female, Glioma, Humans, Male, Mice, Proteogenomics, Survival Analysis, Tumor Microenvironment
Abstract

Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9-11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A (H3.3K27M), or through overexpression of EZHIP in patients harboring wildtype H3. The recent World Health Organizations 5th Classification of CNS Tumors now designates DMG as, H3 K27-altered, suggesting that global H3K27me3 hypomethylation is a ubiquitous feature of DMG and drives devastating transcriptional programs for which there are no treatments. H3-alterations co-segregate with various other somatic driver mutations, highlighting the high-level of intertumoral heterogeneity of DMG. Furthermore, DMG is also characterized by very high-level intratumoral diversity with tumors harboring multiple subclones within each primary tumor. Each subclone contains their own combinations of driver and passenger lesions that continually evolve, making precision-based medicine challenging to successful execute. Whilst the intertumoral heterogeneity of DMG has been extensively investigated, this is yet to translate to an increase in patient survival. Conversely, our understanding of the non-genomic factors that drive the rapid growth and fatal nature of DMG, including endogenous and exogenous microenvironmental influences, neurological cues, and the posttranscriptional and posttranslational architecture of DMG remains enigmatic or at best, immature. However, these factors are likely to play a significant role in the complex biological sequelae that drives the disease. Here we summarize the heterogeneity of DMG and emphasize how analysis of the posttranslational architecture may improve treatment paradigms. We describe factors that contribute to treatment response and disease progression, as well as highlight the potential for pharmaco-proteogenomics (i.e., the integration of genomics, proteomics and pharmacology) in the management of this uniformly fatal cancer.

Published
2022

10. Considerations when treating high-grade pediatric glioma patients with immunotherapy

Author

Crotty, Erin, Downey, Kira, Ferrerosa, Lauren, Flores, Catherine, Hegde, Bindu, Raskin, Scott, Hwang, Eugene, Vitanza, Nicholas, and Okada, Hideho

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Brain Cancer, Clinical Research, Rare Diseases, Orphan Drug, Immunotherapy, Pediatric, Neurosciences, Clinical Trials and Supportive Activities, Brain Disorders, Cancer, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Good Health and Well Being, Brain Neoplasms, Child, Glioma, Humans, Biological correlates, clinical trial design, diffuse intrinsic pontine glioma, diffuse midline glioma, high-grade glioma, immunotherapy, toxicity, Pharmacology and Pharmaceutical Sciences, Neurology & Neurosurgery, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

IntroductionChildren with high-grade gliomas (pHGGs) represent a clinical population in substantial need of new therapeutic options given the inefficacy and toxicity of current standard-of-care modalities. Although immunotherapy has emerged as a promising modality, it has yet to elicit a significant survival benefit for pHGG patients. While preclinical studies address a variety of underlying challenges, translational clinical trial design and management also need to reflect the most updated progress and lessons from the field.Areas coveredThe authors will focus our discussion on the design of clinical trials, the management of potential toxicities, immune monitoring, and novel biomarkers. Clinical trial design should integrate appropriate patient populations, novel, and preclinically optimized trial design, and logical treatment combinations, particularly those which synergize with standard of care modalities. However, there are caveats due to the nature of immunotherapy trials, such as patient selection bias, evidenced by the frequent exclusion of patients on high-dose corticosteroids. Robust immune-modulating effects of modern immunotherapy can have toxicities. As such, it is important to understand and manage these, especially in pHGG patients.Expert opinionAdequate integration of these considerations should allow us to effectively gain insights on biological activity, safety, and biomarkers associated with benefits for patients.

Published
2021

11. Tumor inflammation-associated neurotoxicity

Author

Mahdi, Jasia, Dietrich, Jorg, Straathof, Karin, Roddie, Claire, Scott, Brian J., Davidson, Tom Belle, Prolo, Laura M., Batchelor, Tracy T., Campen, Cynthia J., Davis, Kara L., Gust, Juliane, Lim, Michael, Majzner, Robbie G., Park, Julie R., Partap, Sonia, Ramakrishna, Sneha, Richards, Rebecca, Schultz, Liora, Vitanza, Nicholas A., Wang, Leo D., Mackall, Crystal L., and Monje, Michelle

Published
2023
Full Text
View/download PDF

13. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma

Author

Noll, Alyssa, Myers, Carrie, Biery, Matthew C., Meechan, Michael, Tahiri, Sophie, Rajendran, Asmitha, Berens, Michael E., Paine, Danyelle, Byron, Sara, Zhang, Jiaming, Winter, Conrad, Pakiam, Fiona, Leary, Sarah E.S., Cole, Bonnie L., Jackson, Evangeline R., Dun, Matthew D., Foster, Jessica B., Evans, Myron K., Pattwell, Siobhan S., Olson, James M., and Vitanza, Nicholas A.

Published
2023
Full Text
View/download PDF

15. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Author

Vitanza, Nicholas A., Ronsley, Rebecca, Choe, Michelle, Henson, Casey, Breedt, Mandy, Barrios-Anderson, Adriel, Wein, Amy, Brown, Christopher, Beebe, Adam, Kong, Ada, Kirkey, Danielle, Lee, Brittany M., Leary, Sarah E.S., Crotty, Erin E., Hoeppner, Corrine, Holtzclaw, Susan, Wilson, Ashley L., Gustafson, Joshua A., Foster, Jessica B., Iliff, Jeffrey J., Goldstein, Hannah E., Browd, Samuel R., Lee, Amy, Ojemann, Jeffrey G., Pinto, Navin, Gust, Juliane, Gardner, Rebecca A., Jensen, Michael C., Hauptman, Jason S., and Park, Julie R.

Published
2023
Full Text
View/download PDF

16. dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region

Author

Levy, Shiri, Somasundaram, Logeshwaran, Raj, Infencia Xavier, Ic-Mex, Diego, Phal, Ashish, Schmidt, Sven, Ng, Weng I., Mar, Daniel, Decarreau, Justin, Moss, Nicholas, Alghadeer, Ammar, Honkanen, Henrik, Sarthy, Jay, Vitanza, Nicholas A., Hawkins, R. David, Mathieu, Julie, Wang, Yuliang, Baker, David, Bomsztyk, Karol, and Ruohola-Baker, Hannele

Published
2022
Full Text
View/download PDF

17. CTPS1 inhibition synergizes with replication stress signaling inhibition inMYC-amplified Group 3 medulloblastoma

Author

Hathaway, Matthew R, primary, Gadek, Katherine E, additional, Jagana, Hawa L, additional, Terrones, Isabella C, additional, Hemenway, John M, additional, Miyaki, Aya, additional, Rajendran, Ashmitha, additional, Meechan, Michael, additional, Elena-Sanchez, Leonel, additional, Vitanza, Nicholas A, additional, Slusher, Barbara S, additional, Pattwell, Siobhan S, additional, and Evans, Myron K, additional

Published
2024
Full Text
View/download PDF

18. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

Author

Vitanza, Nicholas A., Johnson, Adam J., Wilson, Ashley L., Brown, Christopher, Yokoyama, Jason K., Künkele, Annette, and Chang, Cindy A.

Subjects
T cells -- Receptors, Antigen receptors, T cell -- Health aspects -- Testing, Nervous system tumors -- Diagnosis -- Development and progression -- Care and treatment, Immunotherapy -- Testing, Tumors in children -- Diagnosis -- Development and progression -- Care and treatment, Biological sciences, Health
Abstract

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective responses in adults with glioblastoma, but the feasibility and tolerability of this approach is yet to be evaluated for pediatric central nervous system (CNS) tumors. Here we show that engineering of a medium-length CAR spacer enhances the therapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orthotopic xenograft medulloblastoma model. We translated these findings into BrainChild-01 (NCT03500991), an ongoing phase 1 clinical trial at Seattle Children's evaluating repetitive locoregional dosing of these HER2-specific CAR T cells to children and young adults with recurrent/refractory CNS tumors, including diffuse midline glioma. Primary objectives are assessing feasibility, safety and tolerability; secondary objectives include assessing CAR T cell distribution and disease response. In the outpatient setting, patients receive infusions via CNS catheter into either the tumor cavity or the ventricular system. The initial three patients experienced no dose-limiting toxicity and exhibited clinical, as well as correlative laboratory, evidence of local CNS immune activation, including high concentrations of CXCL10 and CCL2 in the cerebrospinal fluid. This interim report supports the feasibility of generating HER2-specific CAR T cells for repeated dosing regimens and suggests that their repeated intra-CNS delivery might be well tolerated and activate a localized immune response in pediatric and young adult patients. In an interim analysis of a phase 1 trial, repeated intracranial infusions of HER2-specific CAR T cells were well tolerated with no observed dose-limiting toxicities in three young adult patients with CNS tumors., Author(s): Nicholas A. Vitanza [sup.1] [sup.2] , Adam J. Johnson [sup.1] [sup.3] , Ashley L. Wilson [sup.1] [sup.3] , Christopher Brown [sup.3] [sup.4] , Jason K. Yokoyama [sup.1] [sup.3] , [...]

Published
2021
Full Text
View/download PDF

19. Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.

Author

Vitanza, Nicholas A., Choe, Michelle, Brown, Christopher, Beebe, Adam, Kong, Ada, Rogers, Lisa, Jacob, Susan, Mano, Elena, Abuan, Kimberly, Mgebroff, Stephanie, Lindgren, Catherine, Gustafson, Joshua A., Wilson, Ashley L., Noll, Alyssa, Ronsley, Rebecca, Crotty, Erin E., Leary, Sarah E. S., Foster, Jessica B., Pinto, Navin, and Gust, Juliane

Subjects
*T cells, *CHIMERIC antigen receptors, *TUMORS in children, *CENTRAL nervous system, *BRAIN tumors
Abstract

BACKGROUND: A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood–brain barrier. To overcome this limitation, preclinical and clinical studies have supported the use of repeated, locoregional intracranial CAR T-cell delivery. However, there is limited literature available describing the process for the involvement of an investigational drug service (IDS) pharmacy, particularly in the setting of a children’s hospital with outpatient dosing for CNS tumors. OBJECTIVES: To describe Seattle Children’s Hospital’s experience in clinically producing CAR T cells and the implementation of IDS pharmacy practices used to deliver more than 300 intracranial CAR T-cell doses to children, as well as to share how we refined the processing techniques from CAR T-cell generation to the thawing of fractionated doses for intracranial delivery. METHODS: Autologous CD4+ and CD8+ T cells were collected and transduced to express HER2, EGFR, or B7-H3–specific CAR T cells. Cryopreserved CAR T cells were thawed by the IDS pharmacy before intracranial delivery to patients with recurrent/refractory CNS tumors or with diffuse intrinsic pontine glioma/diffuse midline glioma. RESULTS: The use of a thaw-and-dilute procedure for cryopreserved individual CAR T-cell doses provides reliable viability and is more efficient than typical thaw-and-wash protocols. Cell viability with the thaw-and-dilute protocol was approximately 75% and was always within 10% of the viability assessed at cryopreservation. Cell viability was preserved through 6 hours after thawing, which exceeded the 1-hour time frame from thawing to infusion. CONCLUSION: As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery. [ABSTRACT FROM AUTHOR]

Published
2024

20. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer

Author

Francis, Alicia, Morgan, Allison M., Waanders, Angela J., Viaene, Angela N., Buccoliero, Anna Maria, Chinnaiyan, Arul M., Leonard, Carina A., Kline, Cassie N., Caporalini, Chiara, Kinsinger, Christopher R., Li, Chunde, Kram, David E., Hanson, Derek, Appert, Elizabeth, Kawaler, Emily A., Raabe, Eric H., Jackson, Eric M., Greenfield, Jeffrey P., Stone, Gabrielle S., Getz, Gad, Grant, Gerald, Teo, Guo Ci, Pollack, Ian F., Cain, Jason E., Foster, Jessica B., Phillips, Joanna J., Palma, July E., Ketchum, Karen A., Ruggles, Kelly V., Blumenberg, Lili, Cornwell, Macintosh, Sarmady, Mahdi, Domagalski, Marcin J., Cieślik, Marcin P., Santi, Mariarita, Li, Marilyn M., Ellis, Matthew J., Wyczalkowski, Matthew A., Connors, Meghan, Scagnet, Mirko, Gupta, Nalin, Edwards, Nathan J., Vitanza, Nicholas A., Vaske, Olena M., Becher, Oren, McGarvey, Peter B., Firestein, Ron, Mueller, Sabine, Winebrake, Samuel G., Dhanasekaran, Saravana Mohan, Cai, Shuang, Partap, Sonia, Patton, Tatiana, Le, Toan, Lorentzen, Travis D., Liu, Wenke, Bocik, William E., Petralia, Francesca, Tignor, Nicole, Reva, Boris, Koptyra, Mateusz, Chowdhury, Shrabanti, Rykunov, Dmitry, Krek, Azra, Ma, Weiping, Zhu, Yuankun, Ji, Jiayi, Calinawan, Anna, Whiteaker, Jeffrey R., Colaprico, Antonio, Stathias, Vasileios, Omelchenko, Tatiana, Song, Xiaoyu, Raman, Pichai, Guo, Yiran, Brown, Miguel A., Ivey, Richard G., Szpyt, John, Guha Thakurta, Sanjukta, Gritsenko, Marina A., Weitz, Karl K., Lopez, Gonzalo, Kalayci, Selim, Gümüş, Zeynep H., Yoo, Seungyeul, da Veiga Leprevost, Felipe, Chang, Hui-Yin, Krug, Karsten, Katsnelson, Lizabeth, Wang, Ying, Kennedy, Jacob J., Voytovich, Uliana J., Zhao, Lei, Gaonkar, Krutika S., Ennis, Brian M., Zhang, Bo, Baubet, Valerie, Tauhid, Lamiya, Lilly, Jena V., Mason, Jennifer L., Farrow, Bailey, Young, Nathan, Leary, Sarah, Moon, Jamie, Petyuk, Vladislav A., Nazarian, Javad, Adappa, Nithin D., Palmer, James N., Lober, Robert M., Rivero-Hinojosa, Samuel, Wang, Liang-Bo, Wang, Joshua M., Broberg, Matilda, Chu, Rosalie K., Moore, Ronald J., Monroe, Matthew E., Zhao, Rui, Smith, Richard D., Zhu, Jun, Robles, Ana I., Mesri, Mehdi, Boja, Emily, Hiltke, Tara, Rodriguez, Henry, Zhang, Bing, Schadt, Eric E., Mani, D.R., Ding, Li, Iavarone, Antonio, Wiznerowicz, Maciej, Schürer, Stephan, Chen, Xi S., Heath, Allison P., Rokita, Jo Lynne, Nesvizhskii, Alexey I., Fenyö, David, Rodland, Karin D., Liu, Tao, Gygi, Steven P., Paulovich, Amanda G., Resnick, Adam C., Storm, Phillip B., Rood, Brian R., and Wang, Pei

Published
2020
Full Text
View/download PDF

21. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Author

Duchatel, Ryan J., primary, Jackson, Evangeline R., additional, Parackal, Sarah G., additional, Kiltschewskij, Dylan, additional, Findlay, Izac J., additional, Mannan, Abdul, additional, Staudt, Dilana E., additional, Thomas, Bryce C., additional, Germon, Zacary P., additional, Laternser, Sandra, additional, Kearney, Padraic S., additional, Jamaluddin, M. Fairuz B., additional, Douglas, Alicia M., additional, Beitaki, Tyrone S., additional, McEwen, Holly P., additional, Persson, Mika L., additional, Hocke, Emily A., additional, Jain, Vaibhav, additional, Aksu, Michael, additional, Manning, Elizabeth E., additional, Murray, Heather C., additional, Verrills, Nicole M., additional, Sun, Claire Xin, additional, Daniel, Paul, additional, Vilain, Ricardo E., additional, Skerrett-Byrne, David A., additional, Nixon, Brett, additional, Hua, Susan, additional, de Bock, Charles E., additional, Colino-Sanguino, Yolanda, additional, Valdes-Mora, Fatima, additional, Tsoli, Maria, additional, Ziegler, David S., additional, Cairns, Murray J., additional, Raabe, Eric H., additional, Vitanza, Nicholas A., additional, Hulleman, Esther, additional, Phoenix, Timothy N., additional, Koschmann, Carl, additional, Alvaro, Frank, additional, Dayas, Christopher V., additional, Tinkle, Christopher L., additional, Wheeler, Helen, additional, Whittle, James R., additional, Eisenstat, David D., additional, Firestein, Ron, additional, Mueller, Sabine, additional, Valvi, Santosh, additional, Hansford, Jordan R., additional, Ashley, David M., additional, Gregory, Simon G., additional, Kilburn, Lindsay B., additional, Nazarian, Javad, additional, Cain, Jason E., additional, and Dun, Matthew D., additional

Published
2024
Full Text
View/download PDF

22. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience

Author

Crotty, Erin E., Leary, Sarah E. S., Geyer, J. Russell, Olson, James M., Millard, Nathan E., Sato, Aimee A., Ermoian, Ralph P., Cole, Bonnie L., Lockwood, Christina M., Paulson, Vera A., Browd, Samuel R., Ellenbogen, Richard G., Hauptman, Jason S., Lee, Amy, Ojemann, Jeffrey G., and Vitanza, Nicholas A.

Published
2020
Full Text
View/download PDF

23. Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature

Author

Michaiel, George, Strother, Douglas, Gottardo, Nicholas, Bartels, Ute, Coltin, Hallie, Hukin, Juliette, Wilson, Beverly, Zelcer, Shayna, Hansford, Jordan R., Hassall, Timothy, AbdelBaki, Mohamed S., Cole, Kristina A., Hoffman, Lindsey, Smiley, Natasha P., Smith, Amy, Vinitsky, Anna, Vitanza, Nicholas A., Wright, Avery, Yeo, Kee K., Chow, Lionel M. L., Vanan, Magimairajan I., Dhall, Girish, Bouffet, Eric, and Lafay-Cousin, Lucie

Published
2020
Full Text
View/download PDF

24. EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)

Author

Jackson, Evangeline, primary, Duchatel, Ryan, additional, Staudt, Dilana, additional, Persson, Mika, additional, Mannan, Abdul, additional, Yadavilli, Sridevi, additional, Parackal, Sarah, additional, Game, Shaye, additional, Chong, Wai Chin, additional, Jayasekara, W Samantha, additional, Grand, Marion Le, additional, Kearney, Padraic, additional, Douglas, Alicia, additional, Findlay, Izac, additional, Germon, Zacary, additional, McEwen, Holly, additional, Beitaki, Tyrone, additional, Patabendige, Adjanie, additional, Skerrett-byrne, David, additional, Nixon, Brett, additional, Smith, Nathan, additional, Day, Bryan, additional, Manoharan, Neevika, additional, Nagabushan, Sumanth, additional, Hansford, Jordan, additional, Govender, Dinisher, additional, McCowage, Geoffrey, additional, Firestein, Ron, additional, Howlett, Meegan, additional, Endersby, Raelene, additional, Gottardo, Nicholas, additional, Alvaro, Frank, additional, Waszak, Sebastian, additional, Larsen, Martin, additional, Sanguino, Yolanda Colino, additional, Valdes-Mora, Fatima, additional, Rakotomalala, Andria, additional, Meignan, Samuel, additional, Pasquier, Eddy, additional, Andre, Nicolas, additional, Hulleman, Esther, additional, Eisenstat, David, additional, Vitanza, Nicholas, additional, Nazarian, Javad, additional, Koschmann, Carl, additional, Mueller, Sabine, additional, Cain, Jason, additional, and Dun, Matthew, additional

Published
2023
Full Text
View/download PDF

25. IMMU-26. MRNA CAR T CELL TRAFFICKING FOLLOWING INTRA-VENTRICULAR ADMINISTRATION IN PRECLINICAL MODELS OF DIFFUSE MIDLINE GLIOMA

Author

Al-atrache, Zein, primary, Mcmanus, Olivia, additional, Harvey, Kyra, additional, Dickson, Conor, additional, Patterson, Luke, additional, Beaubien, Ezra, additional, Wilson, Cullen, additional, Hajeebu, Sreehita, additional, Keil, Samantha, additional, Braun, Molly, additional, Meechan, Michael, additional, Vitanza, Nicholas, additional, Iliff, Jeffrey, additional, Madsen, Peter, additional, and Foster, Jessica, additional

Published
2023
Full Text
View/download PDF

26. EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA

Author

Duchatel, Ryan, primary, Jackson, Evangeline, additional, Parackal, Sarah, additional, Sun, Claire, additional, Daniel, Paul, additional, Mannan, Abdul, additional, Findlay, Izac, additional, Staudt, Dilana, additional, Germon, Zacary, additional, Laternser, Sandra, additional, Kiltschewskij, Dylan, additional, Kearney, Padraic, additional, Jamaluddin, M Fairuz B, additional, Douglas, Alicia, additional, Beitaki, Tyrone, additional, Perrson, Mika, additional, Thomas, Bryce, additional, Manning, Elizabeth, additional, Murray, Heather, additional, Verrills, Nikki, additional, Vilain, Ricardo, additional, Skerrett-byrne, David, additional, Nixon, Brett, additional, Hua, Susan, additional, DeBock, Charles, additional, Valdes-Mora, Fatima, additional, Tsoli, Maria, additional, Ziegler, David, additional, Cairns, Murray, additional, Raabe, Eric, additional, Vitanza, Nicholas, additional, Phoenix, Timothy, additional, Koschmann, Carl, additional, Alvaro, Frank, additional, Dayas, Christopher, additional, Tinkle, Christopher, additional, Eisenstat, David, additional, Firestein, Ron, additional, Mueller, Sabine, additional, Nazarian, Javad, additional, Cain, Jason, additional, and Dun, Matthew, additional

Published
2023
Full Text
View/download PDF

32. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

Author

Odia, Yazmin, Koschmann, Carl, Vitanza, Nicholas A, Blank, Peter de, Aguilera, Dolly, Allen, Jeffrey, Daghistani, Doured, Hall, Matthew, Khatib, Ziad, Kline, Cassie, MacDonald, Tobey, Mueller, Sabine, Faison, Shamia L, Allen, Joshua E, Naderer, Odin J, Ramage, Samuel C, Tarapore, Rohinton S, McGovern, Susan Lynne, Khatua, Soumen, and Zaky, Wafik

Published
2024
Full Text
View/download PDF

33. Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Author

Jackson, Evangeline R., primary, Duchatel, Ryan J., primary, Staudt, Dilana E., primary, Persson, Mika L., primary, Mannan, Abdul, primary, Yadavilli, Sridevi, primary, Parackal, Sarah, primary, Game, Shaye, primary, Chong, Wai Chin, primary, Jayasekara, W. Samantha N., primary, Grand, Marion Le, primary, Kearney, Padraic S., primary, Douglas, Alicia M., primary, Findlay, Izac J., primary, Germon, Zacary P., primary, McEwen, Holly P., primary, Beitaki, Tyrone S., primary, Patabendige, Adjanie, primary, Skerrett-Byrne, David A., primary, Nixon, Brett, primary, Smith, Nathan D., primary, Day, Bryan, primary, Manoharan, Neevika, primary, Nagabushan, Sumanth, primary, Hansford, Jordan R., primary, Govender, Dinisha, primary, McCowage, Geoff B., primary, Firestein, Ron, primary, Howlett, Meegan, primary, Endersby, Raelene, primary, Gottardo, Nicholas G., primary, Alvaro, Frank, primary, Waszak, Sebastian M., primary, Larsen, Martin R., primary, Colino-Sanguino, Yolanda, primary, Valdes-Mora, Fatima, primary, Rakotomalala, Andria, primary, Meignan, Samuel, primary, Pasquier, Eddy, primary, André, Nicolas, primary, Hulleman, Esther, primary, Eisenstat, David D., primary, Vitanza, Nicholas A., primary, Nazarian, Javad, primary, Koschmann, Carl, primary, Mueller, Sabine, primary, Cain, Jason E., primary, and Dun, Matthew D., primary

Published
2023
Full Text
View/download PDF

34. Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Author

Jackson, Evangeline R., primary, Duchatel, Ryan J., primary, Staudt, Dilana E., primary, Persson, Mika L., primary, Mannan, Abdul, primary, Yadavilli, Sridevi, primary, Parackal, Sarah, primary, Game, Shaye, primary, Chong, Wai Chin, primary, Jayasekara, W. Samantha N., primary, Grand, Marion Le, primary, Kearney, Padraic S., primary, Douglas, Alicia M., primary, Findlay, Izac J., primary, Germon, Zacary P., primary, McEwen, Holly P., primary, Beitaki, Tyrone S., primary, Patabendige, Adjanie, primary, Skerrett-Byrne, David A., primary, Nixon, Brett, primary, Smith, Nathan D., primary, Day, Bryan, primary, Manoharan, Neevika, primary, Nagabushan, Sumanth, primary, Hansford, Jordan R., primary, Govender, Dinisha, primary, McCowage, Geoff B., primary, Firestein, Ron, primary, Howlett, Meegan, primary, Endersby, Raelene, primary, Gottardo, Nicholas G., primary, Alvaro, Frank, primary, Waszak, Sebastian M., primary, Larsen, Martin R., primary, Colino-Sanguino, Yolanda, primary, Valdes-Mora, Fatima, primary, Rakotomalala, Andria, primary, Meignan, Samuel, primary, Pasquier, Eddy, primary, André, Nicolas, primary, Hulleman, Esther, primary, Eisenstat, David D., primary, Vitanza, Nicholas A., primary, Nazarian, Javad, primary, Koschmann, Carl, primary, Mueller, Sabine, primary, Cain, Jason E., primary, and Dun, Matthew D., primary

Published
2023
Full Text
View/download PDF

35. A Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytomas Treated with Laser Interstitial Thermal Therapy, Open Surgical Resection, and mTOR Inhibitors

Author

Boop, Scott, primary, Bonda, David, additional, Randle, Stephanie, additional, Leary, Sarah, additional, Vitanza, Nicholas, additional, Crotty, Erin, additional, Novotny, Edward, additional, Friedman, Seth, additional, Ellenbogen, Richard G., additional, Durfy, Sharon, additional, Goldstein, Hannah, additional, Ojemann, Jeffrey G., additional, and Hauptman, Jason S., additional

Published
2023
Full Text
View/download PDF

36. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Author

Jackson, Evangeline R., primary, Duchatel, Ryan J., additional, Staudt, Dilana E., additional, Persson, Mika L., additional, Mannan, Abdul, additional, Yadavilli, Sridevi, additional, Parackal, Sarah, additional, Game, Shaye, additional, Chong, Wai Chin, additional, Jayasekara, W. Samantha N., additional, Grand, Marion Le, additional, Kearney, Padraic S., additional, Douglas, Alicia M., additional, Findlay, Izac J., additional, Germon, Zacary P., additional, McEwen, Holly P., additional, Beitaki, Tyrone S., additional, Patabendige, Adjanie, additional, Skerrett-Byrne, David A., additional, Nixon, Brett, additional, Smith, Nathan D., additional, Day, Bryan, additional, Manoharan, Neevika, additional, Nagabushan, Sumanth, additional, Hansford, Jordan R., additional, Govender, Dinisha, additional, McCowage, Geoff B., additional, Firestein, Ron, additional, Howlett, Meegan, additional, Endersby, Raelene, additional, Gottardo, Nicholas G., additional, Alvaro, Frank, additional, Waszak, Sebastian M., additional, Larsen, Martin R., additional, Colino-Sanguino, Yolanda, additional, Valdes-Mora, Fatima, additional, Rakotomalala, Andria, additional, Meignan, Samuel, additional, Pasquier, Eddy, additional, André, Nicolas, additional, Hulleman, Esther, additional, Eisenstat, David D., additional, Vitanza, Nicholas A., additional, Nazarian, Javad, additional, Koschmann, Carl, additional, Mueller, Sabine, additional, Cain, Jason E., additional, and Dun, Matthew D., additional

Published
2023
Full Text
View/download PDF

38. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Author

Duchatel, Ryan J, primary, Jackson, Evangeline R, additional, Parackal, Sarah G., additional, Sun, Claire, additional, Daniel, Paul, additional, Mannan, Abdul, additional, Findlay, Izac J, additional, Staudt, Dilana, additional, Germon, Zacary P, additional, Laternser, Sandra, additional, Kiltschewskij, Dylan, additional, Kearney, Padraic S, additional, Jamaluddin, Muhummad Fairuz B., additional, Douglas, Alicia M, additional, Beitaki, Tyrone, additional, Perrson, Mika, additional, Manning, Elizabeth E, additional, Murray, Heather C, additional, Verrills, Nicole M, additional, Skerrett-Byrne, David A, additional, Nixon, Brett, additional, Hua, Susan, additional, Valdes Mora, Fatima, additional, Tsoli, Maria, additional, Ziegler, David S, additional, Cairns, Murray J, additional, Raabe, Eric H, additional, Vitanza, Nicholas A, additional, Koschmann, Carl, additional, Alvaro, Frank, additional, Dayas, Christopher V, additional, Tinkle, Christopher, additional, Eisenstat, David, additional, Firestein, Ron, additional, Mueller, Sabine, additional, Nazarian, Javad, additional, Cain, Jason, additional, and Dun, Matthew D, additional

Published
2023
Full Text
View/download PDF

39. Abstract LB121: BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults

Author

Vitanza, Nicholas A., primary, Gust, Juliane, additional, Ronsley, Rebecca, additional, Wilson, Ashley L., additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Albert, Catherine M., additional, Pinto, Navin, additional, Orentas, Rimas J., additional, Gardner, Rebecca A., additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2023
Full Text
View/download PDF

41. Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Author

Vitanza, Nicholas A., primary, Wilson, Ashley L., primary, Huang, Wenjun, primary, Seidel, Kristy, primary, Brown, Christopher, primary, Gustafson, Joshua A., primary, Yokoyama, Jason K., primary, Johnson, Adam J., primary, Baxter, Blake A., primary, Koning, Ryan W., primary, Reid, Aquene N., primary, Meechan, Michael, primary, Biery, Matthew C., primary, Myers, Carrie, primary, Rawlings-Rhea, Stephanie D., primary, Albert, Catherine M., primary, Browd, Samuel R., primary, Hauptman, Jason S., primary, Lee, Amy, primary, Ojemann, Jeffrey G., primary, Berens, Michael E., primary, Dun, Matthew D., primary, Foster, Jessica B., primary, Crotty, Erin E., primary, Leary, Sarah E.S., primary, Cole, Bonnie L., primary, Perez, Francisco A., primary, Wright, Jason N., primary, Orentas, Rimas J., primary, Chour, Tony, primary, Newell, Evan W., primary, Whiteaker, Jeffrey R., primary, Zhao, Lei, primary, Paulovich, Amanda G., primary, Pinto, Navin, primary, Gust, Juliane, primary, Gardner, Rebecca A., primary, Jensen, Michael C., primary, and Park, Julie R., primary

Published
2023
Full Text
View/download PDF

43. Functional genomic analysis of adult and pediatric brain tumor isolates

Author

Hoellerbauer, Pia, primary, Biery, Matt C., additional, Arora, Sonali, additional, Rao, Yiyun, additional, Girard, Emily J., additional, Mitchell, Kelly, additional, Dighe, Pratiksha, additional, Kufeld, Megan, additional, Kuppers, Daniel A., additional, Herman, Jacob A., additional, Holland, Eric C., additional, Soroceanu, Liliana, additional, Vitanza, Nicholas A., additional, Olson, James M., additional, Pritchard, Justin R., additional, and Paddison, Patrick J., additional

Published
2023
Full Text
View/download PDF

44. CSIG-10. PHARMACO-PHOSPHO-PROTEO-GENOMICS OF PEDIATRIC HIGH-GRADE GLIOMAS – A PILOT STUDY

Author

Findlay, Izac, primary, Staudt, Dilana, additional, Kearney, Padraic, additional, McEwen, Holly, additional, Duchatel, Ryan, additional, Jackson, Evangeline, additional, Beitaki, Tyrone, additional, Smith, Nathan, additional, Vitanza, Nicholas, additional, Firestein, Ron, additional, Cain, Jason, additional, Mueller, Sabine, additional, Pasquier, Eddy, additional, Koschmann, Carl, additional, Hulleman, Esther, additional, Nazarian, Javad, additional, Hansen, Mitchell, additional, Alvaro, Frank, additional, Davis, Melissa, additional, Waszak, Sebastian, additional, and Dun, Matthew, additional

Published
2022
Full Text
View/download PDF

45. CSIG-09. THERAPEUTIC TARGETING OF PRENATAL PONTINE ID1 SIGNALING IN DIFFUSE MIDLINE GLIOMA

Author

Messinger, Dana, primary, Harris, Micah, additional, Cummings, Jessica, additional, Thomas, Chase, additional, Yang, Tao, additional, Sweha, Stefan, additional, Woo, Rinette, additional, Siddaway, Robert, additional, Burkert, Martin, additional, Stallard, Stefanie, additional, Qin, Tingting, additional, Mullan, Brendan, additional, Siada, Ruby, additional, Ravindran, Ramya, additional, Niculcea, Michael, additional, Dowling, Abigail, additional, Bradin, Joshua, additional, Ginn, Kevin, additional, Gener, Melissa, additional, Dorris, Kathleen, additional, Vitanza, Nicholas, additional, Schmidt, Susanne, additional, Spitzer, Jasper, additional, Li, Jiang, additional, Filbin, Mariella, additional, Cao, Xuhong, additional, Castro, Maria, additional, Lowenstein, Pedro, additional, Mody, Rajen, additional, Chinnaiyan, Arul, additional, Desprez, Pierre-Yves, additional, McAllister, Sean, additional, Dun, Matthew, additional, Hawkins, Cynthia, additional, Waszak, Sebastian, additional, Venneti, Sriram, additional, Koschmann, Carl, additional, and Yadav, Viveka, additional

Published
2022
Full Text
View/download PDF

46. EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA

Author

Jackson, Evangeline, primary, Duchatel, Ryan, additional, Persson, Mika, additional, Mannan, Abdul, additional, Yadavilli, Sridevi, additional, Parackal, Sarah, additional, Game, Shaye, additional, Chong, Wai Chin, additional, Jayasekara, Samantha, additional, Le Grand, Marion, additional, Kearney, Padraic, additional, Douglas, Alicia, additional, Findlay, Izac, additional, Staudt, Dilana, additional, Germon, Zacary, additional, Skerrett-Byrne, David, additional, Nixon, Brett, additional, Smith, Nathan, additional, Hulleman, Esther, additional, Day, Bryan, additional, McCowage, Geoffrey, additional, Alvaro, Frank, additional, Waszak, Sebastian, additional, Larsen, Martin, additional, Colino-Sanguino, Yolanda, additional, Valdes-Mora, Fatima, additional, Rakotomalala, Andria, additional, Meignan, Samuel, additional, Pasquier, Eddy, additional, Vitanza, Nicholas, additional, Nazarian, Javad, additional, Koschmann, Carl, additional, Cain, Jason, additional, Mueller, Sabine, additional, and Dun, Matthew, additional

Published
2022
Full Text
View/download PDF

47. TMIC-06. ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO

Author

Persson, Mika, primary, Jackson, Evangeline, additional, Duchatel, Ryan, additional, Bramberger, Liesl, additional, McEwen, Holly, additional, Kearney, Padraic, additional, Findlay, Izac, additional, Douglas, Alicia, additional, Kobbe, Birgit, additional, Wagener, Raimund, additional, Larsen, Martin, additional, Faridi, Pouya, additional, Holst, Jeff, additional, Mayall, Jemma, additional, Gedye, Craig, additional, Hondermarck, Hubert, additional, Horvat, Jay, additional, Nixon, Brett, additional, Cartaxo, Rodrigo, additional, Koschmann, Carl, additional, Valdes-Mora, Fatima, additional, Ortega, David Gallego, additional, Nazarian, Javad, additional, Alonso, Marta M, additional, Hulleman, Esther, additional, Van der Lugt, Jasper, additional, Vitanza, Nicholas, additional, Mueller, Sabine, additional, and Dun, Matthew, additional

Published
2022
Full Text
View/download PDF

48. Blood-brain barrier–adapted precision medicine therapy for pediatric brain tumors

Author

Marini, Bernard L., Benitez, Lydia L., Zureick, Andrew H., Salloum, Ralph, Gauthier, Angela C., Brown, Julia, Wu, Yi-Mi, Robinson, Dan R., Kumar, Chandan, Lonigro, Robert, Vats, Pankaj, Cao, Xuhong, Kasaian, Katayoon, Anderson, Bailey, Mullan, Brendan, Chandler, Benjamin, Linzey, Joseph R., Camelo-Piragua, Sandra I., Venneti, Sriram, McKeever, Paul E., McFadden, Kathryn A., Lieberman, Andrew P., Brown, Noah, Shao, Lina, Leonard, Marcia A.S., Junck, Larry, McKean, Erin, Maher, Cormac O., Garton, Hugh J.L., Muraszko, Karin M., Hervey-Jumper, Shawn, Mulcahy-Levy, Jean M., Green, Adam, Hoffman, Lindsey M., Dorris, Katie, Vitanza, Nicholas A., Wang, Joanne, Schwartz, Jonathan, Lulla, Rishi, Smiley, Natasha Pillay, Bornhorst, Miriam, Haas-Kogan, Daphne A., Robertson, Patricia L., Chinnaiyan, Arul M., Mody, Rajen, and Koschmann, Carl

Published
2017
Full Text
View/download PDF

49. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Author

Vitanza, Nicholas A., primary, Wilson, Ashley L., additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Brown, Christopher, additional, Gustafson, Joshua A., additional, Yokoyama, Jason K., additional, Johnson, Adam J., additional, Baxter, Blake A., additional, Koning, Ryan W., additional, Reid, Aquene N., additional, Meechan, Michael, additional, Biery, Matthew C., additional, Myers, Carrie, additional, Rawlings-Rhea, Stephanie D., additional, Albert, Catherine M., additional, Browd, Samuel R., additional, Hauptman, Jason S., additional, Lee, Amy, additional, Ojemann, Jeffrey G., additional, Berens, Michael E., additional, Dun, Matthew D., additional, Foster, Jessica B., additional, Crotty, Erin E., additional, Leary, Sarah E.S., additional, Cole, Bonnie L., additional, Perez, Francisco A., additional, Wright, Jason N., additional, Orentas, Rimas J., additional, Chour, Tony, additional, Newell, Evan W., additional, Whiteaker, Jeffrey R., additional, Zhao, Lei, additional, Paulovich, Amanda G., additional, Pinto, Navin, additional, Gust, Juliane, additional, Gardner, Rebecca A., additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2022
Full Text
View/download PDF

50. SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA

Author

Odia, Yazmin, primary, Koschmann, Carl, additional, Tarapore, Rohinton, additional, Allen, Jeffrey, additional, Hall, Matthew, additional, Daghistani, Doured, additional, Khatib, Ziad, additional, Aguilera, Dolly, additional, MacDonald, Tobey, additional, de Blank, Peter, additional, McGovern, Susan Lynne, additional, Mueller, Sabine, additional, Kline, Cassie, additional, Vitanza, Nicholas, additional, Allen, Joshua E, additional, Zaky, Wafik, additional, and Gardner, Sharon, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results